Injection Site Reactions Some people notice redness, itching, or slight swelling at the site where the medication was injected
the dose of each of the PDE-5 inhibitor and PT-141 given as multiple agent therapy may be such as would be, for a particular patient, less than a therapeutic dose of either agent administered as monotherapy
Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes [J]
Medical Considerations and Provider Guidance GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used cautiously in those with a history of pancreatitis or diabetic retinopathy
Sulfonylurea drugs such as glipizide (Glucotrol XL), glimepiride (Amaryl), or glyburide (DiaBeta, Glynase)